The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study

Inclusion Criteria

• •Age ≥ 18 years old, male or female not limited
• •Non resectable HCC patients diagnosed by tissue/cytology or imaging that meets the diagnostic criteria for HCC
• •There must be at least one measurable lesion (RECIST 1.1)
• •Use immunotherapy combination therapy as first-line treatment, including atezolizumab+bevacizumab, sintilizumab+bevacizumab analogs, carrelizumab+apatinib, lenvatinib+tirelizumab or sintilizumab, with or without local treatment (including but not limited to TACE, HAIC)
• •Have not received systematic anti-tumor treatment in the past
• •Child Pugh 5-7 points
• •ECOG PS 0-1 points
• •Prospective cohort requires patients to have at least one imaging tumor evaluation since baseline;